Skip to main content

Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources

Written by Customer Service on . Posted in Public Companies.

EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson will be responsible for Antares’ corporate Human Resources (“HR”) strategy and development.

Claude E. Richardson has more than 25 years of Human Resources leadership experience across multiple industries including pharmaceutical, industrials, financial services and consumer products. His broad-based background in Human Resources includes talent management and acquisition, compensation and benefits, development and training, performance management, organizational assessment, change management and HR strategy.

Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, “We are excited to welcome Claude to the executive leadership team at this juncture of our growth. Claude has an extensive Human Resources background that we expect will prove valuable in this new role as we continue to grow and expand. Employee engagement and a high-performance culture are key focuses for Antares, and we believe Claude will have a positive impact in these areas as well as emphasizing the acceleration of diversity, equity and inclusion efforts across the Company’s initiatives. We look forward to leveraging his proven ability to develop and manage an HR strategy that will drive performance and support our future growth.”

Prior to joining Antares, Mr. Richardson was Senior Vice President, Chief Human Resources Officer at Delta Dental of NJ/CT, a regional dental insurer with approximately 300 employees. Previously, he was Vice President, Global Human Resources at Ametek, Inc., an industrials company with approximately 18,000 employees worldwide. Prior to that, Mr. Richardson has held other senior Human Resources roles at an impressive roster of organizations including Lockheed Martin, Lubrizol Corporation, Johnson & Johnson, Citigroup, The Gillette Corporation and Texas Instruments. Mr. Richardson was also a decorated Officer in the United States Marine Corps. He earned his Bachelor of Science in General Engineering from the U.S. Naval Academy and Executive Masters in Human Resources Leadership from Rutgers University, School of Management and Labor Relations.

“I appreciate the opportunity to join Antares to lead their Human Resources strategy and development. I believe my comprehensive HR background will support the Company’s expansion and growth trajectory. I look forward to working with everyone at Antares to build and strengthen a collaborative environment for continued success,” added Mr. Richardson.

About Antares Pharma

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s FDA-approved products include XYOSTED® (testosterone enanthate) injection and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S. and expects to commercially launch TLANDO® (testosterone undecanoate) in the U.S. pending final FDA approval.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Company’s ability to achieve the updated 2021 full-year revenue guidance; the uncertainty regarding the ongoing COVID-19 pandemic, including new strains of the virus, and the mitigation measures and other restrictions implemented in response to the same and the impact on demand for our products, new patients and prescriptions, future revenue, product supply, clinical trials, and our overall business, operating results and financial condition; the timing and results of the Company’s or its partners’ research projects or clinical trials of product candidates in development; actions by the FDA or other regulatory agencies with respect to the Company’s products or product candidates of its partners; commercial success of the Company’s products or partner products and continued growth in product, development, licensing and royalty revenue;; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ”may”, ”will”, ”should”, ”would”, ”expect”, ”intend”, ”plan”, ”anticipate”, ”believe”, ”estimate”, ”predict”, ”potential”, ”seem”, ”seek”, ”future”, ”continue”, or ”appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, and in the Company’s other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

Contact:
Tram Bui
Vice President, Corporate Communications and Investor Relations
609-359-3016
tbui@antarespharma.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.